Disease relevance of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• Gadobutrol (1.0 mol/L) was injected intravenously at randomly assigned doses of either 0.1 or 0.3 mmol per kilogram of body weight [1].
• Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma [2].
• Malignant melanoma cells of human origin were irradiated in the presence or absence of Gadobutrol [3].
• Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure [4].
• Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials [5].

High impact information on 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• PURPOSE: To assess the potential advantages of using a 1.0 mol/L versus 0.5 mol/L gadobutrol formulation for magnetic resonance (MR) brain perfusion imaging [6].
• The lack of difference regarding relative regional cerebral blood volume maps was consistent with the use of the same dose of each gadobutrol formulation [6].
• Changes in vital signs, clinical chemistry, and urinalysis results, including creatinine clearance, were monitored before, at 6 hours, and then every 24 hours until 72 hours (group 1) or 120 hours (group 2) after intravenous injection of gadobutrol [1].
• RATIONALE AND OBJECTIVE: The objective of this study was to compare 0.1 and 0.2 mmol/kg body weight (bw) doses gadobenate dimeglumine (Gd-BOPTA; MultiHance) and gadobutrol (Gd-BT-DO3A; Gadovist) for cerebral perfusion magnetic resonance (MR) imaging at 1.5 T [7].
• OBJECTIVES: We sought to determine the relaxivity and accurate relaxation rates of Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA at 0.2, 1.5, and 3 T in human blood plasma [8].

Chemical compound and disease context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• METHODS: In 8 domestic pigs (35 +/- 4 kg body weight [BW]), continuous spiral CTs of the chest and abdomen were performed using either 2 mmol/kg BW Gadovist 1.0 (1 mol/L gadobutrol) intravenously or Ultravist (300 mg I/mL iopromide) (slice 5 mm, table feed 7.5 mm, reconstruction increment 5 mm) [9].
• In the ten patients, gadobutrol-based total-body MRA accurately assessed significant stenoses (luminal narrowing > 50%) with sensitivities and specificities of 96.2% (95% CI 0.83-0.97) and 95.7% (95% CI 0.84-0.96), respectively, compared to digital subtraction angiography [10].

Biological context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• An examination of 16 young swine, which were given different amounts of gadobutrol through inhalation, was performed [11].
• The renal excretion rate was linear over the large dose range tested, indicating dose-proportionate, first-order kinetics of gadobutrol [12].
• RATIONALE AND OBJECTIVES: To investigate the pharmacokinetics of 1M gadobutrol as a new neutral MR contrast agent in patients with impaired renal function [4].
• RESULTS: No gadobutrol-related changes in hematology, clinical chemistry, or vital signs were detected at either dose level during the observation period [13].
• Intravenous injection of 1.0-M gadobutrol at a dose of up to 0.1 0.27 mmol/kg b.w. in the indication CE MRA is safe and causes no clinically relevant changes in safety parameters such as heart rate, blood pressure, blood and urine laboratory values, and cardiac conduction system [14].

Anatomical context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• Maximum signal intensity changes and best peak profiles during first pass of the right and left ventricle were observed with a dose of 0.03 mmol Gd/kg bw gadobutrol using T1-weighted Turbo-FLASH [15].
• Furthermore, the investigation of metastatic lymph nodes is required to evaluate the further potential of gadobutrol for interstitial MR lymphography [16].
• CONCLUSION: Gadobutrol is suitable for interstitial MR lymphography, as it rapidly appears in the lymphatic system [16].
• Comparison of 0.5-M Gd-DTPA with 1.0-M gadobutrol for magnetic resonance angiography of the supplying arteries of the spinal cord in thoracoabdominal aortic aneurysm patients [17].
• RESULTS: In vivo, the mean peak enhancement 5, 15, 30, and 120 seconds in the abdominal aorta after injection of 2 mL/kg BW gadobutrol and iopromide was 200 +/- 11, 224 +/- 10, 261 +/- 13, and 95 +/- 9 HU versus 232 +/- 10, 298 +/- 10, 152 +/- 11, and 123 +/- 10 HU, respectively [9].

Associations of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid with other chemical compounds

• Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study [18].
• Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso [19].
• RATIONALE AND OBJECTIVES: To evaluate prospectively diagnostic accuracy of 1 mol/L gadobutrol as a contrast agent for intraarterial x-ray digital subtraction angiography (DSA) in comparison to iodinated, nonionic contrast media and 0.5 mol/L gadolinium-DTPA [20].
• We were able to show the suitability of liposome-encapsulated gadobutrol as an interstitially injectable lymphography contrast agent in an experimental animal model [21].

Gene context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• CONCLUSION: Contrast-enhanced CT with 1 mol/L gadobutrol in a dose of 2 mmol/kg BW resulted in an excellent vascular and parenchymal enhancement in most vascular regions and parenchymal organs similar to an equivalent volume of 300 mg/mL iodinated contrast media [9].
• The purpose of this study was to compare moving-table three-dimensional contrast-enhanced magnetic resonance angiography (CE MRA), using 1.0-mol gadobutrol, with intra-arterial digital subtraction angiography (i.a. DSA) for evaluation of pelvic and peripheral arteries in patients with peripheral arterial occlusive disease [22].

Analytical, diagnostic and therapeutic context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• X-ray digital subtraction angiography with 1 mol/L gadobutrol: results from a comparative porcine study With iodinated contrast agents [20].
• Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers [12].
• RATIONALE AND OBJECTIVE: To evaluate the contrast kinetics of gadobutrol for interstitial MR lymphography [16].
• Pulmonary resorption of inhaled gadobutrol in an animal model: usage to determine lung diffusion in MRI examinations [11].
• Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol [3].

References